All In Biotech

Drug Trial Radar · NCT05067582

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two-Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults With Autism Spectrum Disorder

Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Jan 25, 2022

Primary completion

Jun 18, 2024

Study completion Jun 21, 2024

Sponsor

Lead sponsor
Yamo Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Oct 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a score of \>/= 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II), and a score of \>/= 4 on the Clinical Global Impression of Severity of Illness (CGI-S) weighted for socialization.

Conditions

  • Autism Spectrum Disorder
  • Autism

Interventions

  • L1-79Drug

    tyrosine hydroxylase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Vineland Adaptive Behavior Scale, Third Edition (Vineland-3), Responder AnalysisTime frame: Week 12

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Southwest Autism Research and Resource Center

    Phoenix, Arizona

  • Thompson Autism Center CHOC

    Orange, California

  • Cortica

    San Rafael, California

  • Rush University

    Chicago, Illinois

  • Thompson Center for Autism and Neurodevelopmental Disorders

    Columbia, Missouri

  • Center for Autism and The Developing Brain

    White Plains, New York

  • Ohio State University

    Columbus, Ohio

  • Red Oak Psychiatry Associates

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.